Hirtle Callaghan & Co Raised Its Stake in Johnson & Johnson (JNJ) by $1.88 Million; As Medical Pptys Trust (MPW) Stock Price Declined, Covalent Partners Lifted Its Position

February 23, 2018 - By Migdalia James

Robert Hockett increased its stake in Medical Pptys Trust Inc (MPW) by 31.33% based on its latest 2017Q3 regulatory filing with the SEC. Covalent Partners Llc bought 155,702 shares as the company’s stock declined 0.60% while stock markets rallied. The hedge fund run by Robert Hockett held 652,702 shares of the consumer services company at the end of 2017Q3, valued at $8.57M, up from 497,000 at the end of the previous reported quarter. Covalent Partners Llc who had been investing in Medical Pptys Trust Inc for a number of months, seems to be bullish on the $4.60 billion market cap company. The stock increased 0.72% or $0.09 during the last trading session, reaching $12.62. About 1.07M shares traded. Medical Properties Trust, Inc. (NYSE:MPW) has declined 4.49% since February 23, 2017 and is downtrending. It has underperformed by 21.19% the S&P500.

Hirtle Callaghan & Co Llc increased its stake in Johnson & Johnson (JNJ) by 3631.84% based on its latest 2017Q3 regulatory filing with the SEC. Hirtle Callaghan & Co Llc bought 14,600 shares as the company’s stock rose 6.85% with the market. The institutional investor held 15,002 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $1.95M, up from 402 at the end of the previous reported quarter. Hirtle Callaghan & Co Llc who had been investing in Johnson & Johnson for a number of months, seems to be bullish on the $351.36B market cap company. The stock increased 0.67% or $0.8766 during the last trading session, reaching $130.7866. About 2.22M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since February 23, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.




Investors sentiment is 0.83 in 2017 Q3. Its the same as in 2017Q2. It is the same, as 45 investors sold JNJ shares while 871 reduced holdings. only 111 funds opened positions while 645 raised stakes. 1.71 billion shares or 0.90% less from 1.73 billion shares in 2017Q2 were reported. Regions Corp accumulated 572,505 shares. Adage Cap Prns Gp Limited Liability Com reported 3.72M shares. Transamerica reported 48,118 shares. Altfest L J & accumulated 20,374 shares or 1.29% of the stock. Grace White Incorporated New York reported 47,466 shares. Heritage Wealth Advsr has 1.09% invested in Johnson & Johnson (NYSE:JNJ). Sei Investments has 1.10M shares. Barr E S And has invested 3.7% in Johnson & Johnson (NYSE:JNJ). Lynch And Assoc In holds 93,966 shares or 4.85% of its portfolio. Truenorth Incorporated has 0.13% invested in Johnson & Johnson (NYSE:JNJ). 15,303 were accumulated by Cwm Limited. First Light Asset Mngmt holds 2,183 shares. Tower Bridge Advsr stated it has 200,268 shares or 2.96% of all its holdings. Berson And Corrado Investment Limited Liability Company reported 0.24% stake. St Germain D J holds 145,938 shares.

Since February 15, 2018, it had 0 buys, and 1 sale for $20.17 million activity.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 12 have Buy rating, 5 Sell and 6 Hold. Therefore 52% are positive. Johnson & Johnson had 89 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was downgraded by Wells Fargo to “Market Perform” on Thursday, January 26. On Tuesday, September 22 the stock rating was initiated by UBS with “Buy”. As per Monday, May 15, the company rating was upgraded by JP Morgan. The stock has “Hold” rating by Piper Jaffray on Tuesday, July 18. The firm earned “Hold” rating on Monday, September 25 by Citigroup. Alembic downgraded the stock to “Underweight” rating in Friday, July 21 report. On Monday, October 5 the stock rating was reinitiated by Piper Jaffray with “Neutral”. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, January 25. The rating was maintained by Cowen & Co on Friday, October 6 with “Buy”. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by Cowen & Co on Tuesday, June 13.

Hirtle Callaghan & Co Llc, which manages about $24.08 billion and $1.01 billion US Long portfolio, decreased its stake in Ishares Msci Emerging Mkts (EEM) by 18,870 shares to 2.71M shares, valued at $121.55M in 2017Q3, according to the filing.

Covalent Partners Llc, which manages about $968.54 million and $147.33M US Long portfolio, decreased its stake in Weatherford Intl Plc (NYSE:WFT) by 1.07 million shares to 946,304 shares, valued at $4.33M in 2017Q3, according to the filing. It also reduced its holding in Community Health Sys Inc New (NYSE:CYH) by 614,205 shares in the quarter, leaving it with 164,795 shares, and cut its stake in Universal Fst Prods Inc (NASDAQ:UFPI).

Among 14 analysts covering Medical Properties Trust (NYSE:MPW), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Medical Properties Trust had 34 analyst reports since September 17, 2015 according to SRatingsIntel. The stock has “Hold” rating by Jefferies on Tuesday, January 12. The stock of Medical Properties Trust, Inc. (NYSE:MPW) has “Buy” rating given on Friday, July 22 by Deutsche Bank. The firm has “Market Perform” rating given on Friday, July 1 by JMP Securities. The rating was maintained by SunTrust on Thursday, November 2 with “Buy”. The stock of Medical Properties Trust, Inc. (NYSE:MPW) earned “Neutral” rating by BTIG Research on Thursday, August 25. The firm has “Hold” rating given on Monday, November 7 by Stifel Nicolaus. The stock of Medical Properties Trust, Inc. (NYSE:MPW) earned “Hold” rating by Deutsche Bank on Wednesday, January 10. The firm earned “Hold” rating on Monday, October 16 by KeyBanc Capital Markets. Jefferies maintained it with “Buy” rating and $15.0 target in Thursday, February 8 report. The stock has “Buy” rating by Jefferies on Friday, June 9.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: